Showing results (561-570 of 673) with videos related to
Sort By:
Pageof 68
The New England Journal of Medicine|July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemiaClaire N Harrison, Peter J Campbell, Georgina Buck, et al.Nature Communications|September 2, 2014
Magnetic properties of uncultivated magnetotactic bacteria and their contribution to a stratified estuary iron cycleA P Chen, V M Berounsky, M K Chan, et al.Blood|May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortPhilip A Beer, Peter J Campbell, Linda M Scott, et al.The New England Journal of Medicine|January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.Journal of Managed Care & Specialty Pharmacy|December 24, 2021
Laboratory monitoring to reduce adverse drug-related events: a mixed methods studyTeresa N Harrison, Kristi Reynolds, Erin E Hahn, et al.European Journal of Haematology|November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapyRuben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.Physical Review Letters|October 15, 2008
Formation of pancakelike Ising domains and giant magnetic coercivity in ferrimagnetic LuFe2O4Weida Wu, V Kiryukhin, H-J Noh, et al.Medicine and Science in Sports and Exercise|March 15, 2024
Mechanisms of Exercise Intolerance Across the Breast Cancer Continuum: A Pooled Analysis of Individual Patient DataJessica M Scott, Jasme Lee, Meghan G Michalski, et al.International Journal of Cardiology. Hypertension|June 22, 2021
COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare systemJaejin An, Hui Zhou, Rong Wei, et al.Pageof 68